Subscribe to Newsletter

Other

Business & Profession Other

Benchmarking Ophthalmology

| Mark Hillen

Our cataloging of the major eye diseases is insightful, even though impact factor analysis is flawed.

Business & Profession Other

Questioning the “Critical Period”

| Mark Hillen

Received wisdom says that there is a critical period after birth during which the brain is wired for sight; blindness then means blindness for life

Business & Profession Professional Development

The Philanthropic Ophthalmologist

| Richard Gallagher

Be it battling blindness one patient at a time or changing global healthcare policies, ophthalmologists demonstrate admirable altruism.

Business & Profession Other

The Ophthalmologist Power List 2014

| Richard Gallagher

Ranking the 100 most influential people in ophthalmology. Which clinicians and researchers have the biggest impact on our field?

Business & Profession Basic & Translational Research

Gene Therapy Clinical Trials

| Irv Arons, Mark Hillen

The EMA approved the first gene therapy agent in 2012 – for lipoprotein lipase deficiency. Might gene therapies for ophthalmic disease reach the wards any time soon?

Business & Profession Retina

20/200 Drivers

| Mark Hillen

Americans love their cars and in many places you’re virtually stranded if you don’t drive. So does vision loss stop elderly Americans from driving?

Business & Profession Cornea / Ocular Surface

Seeing What’s Behind the Camera

| Mark Hillen

The pupil of the eye is dark, and the cornea highly reflective – it acts as a mirror. Combine this with high resolution photography, and you get a whole new vista.

Business & Profession Other

Will Eye Bling Take Off?

| Mark Hillen

The media have been building up “eyeball jewelry” as a potential craze, but the evidence suggests otherwise

Business & Profession Other

The Lore of Levofloxacin

Expert opinion: infection prevention & treatment in photorefractive surgery patients.

Business & Profession Basic & Translational Research

Stem Cell Clinical Trials

| Irv Arons, Mark Hillen

Therapies based on stem cell treatments are considered to have tremendous potential in medicine.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: